{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "10", "@year": "2020", "@timestamp": "2020-01-10T04:25:54.000054-05:00", "@month": "01"}, "ait:date-sort": {"@day": "01", "@year": "2016", "@month": "06"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": [{"xocs:funding-agency-matched-string": "Merck, Sharp and Dohme Corp., and Grant for Chula Research Scholar"}, {"xocs:funding-agency-matched-string": "Ratchadaphiseksomphot Endowment Fund"}, {"xocs:funding-agency-matched-string": "Chulalongkorn University", "xocs:funding-agency-acronym": "CU", "xocs:funding-agency": "Chulalongkorn University", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100002873", "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"}], "xocs:funding-addon-generated-timestamp": "2021-02-02T04:27:41.590424Z", "xocs:funding-text": "This work was funded by Merck, Sharp and Dohme Corp., and Grant for Chula Research Scholar, Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University. The study was also supported by Research Unit of Hepatitis and Liver Cancer and Center of Excellence in Clinical Virology, Chulalongkorn University.", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "address-part": "Rama IV road", "postal-code": "10330", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Research Unit of Hepatitis and Liver Cancer"}, {"$": "Department of Biochemistry"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "112978483"}, "@dptid": "112978483"}, "author": [{"ce:given-name": "Pisit", "preferred-name": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, "@seq": "1", "ce:initials": "P.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Tangkijvanich", "@auid": "7003646635", "ce:indexed-name": "Tangkijvanich P."}, {"preferred-name": {"ce:given-name": "A.", "ce:initials": "A.", "ce:surname": "Khlaiphuengsin", "ce:indexed-name": "Khlaiphuengsin A."}, "@seq": "5", "ce:initials": "A.", "@_fa": "true", "@type": "auth", "ce:surname": "Khlaiphuengsin", "@auid": "56784235600", "ce:indexed-name": "Khlaiphuengsin A."}, {"preferred-name": {"ce:given-name": "N.", "ce:initials": "N.", "ce:surname": "Chuaypen", "ce:indexed-name": "Chuaypen N."}, "@seq": "6", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Chuaypen", "@auid": "55885029700", "ce:indexed-name": "Chuaypen N."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113019942"}, "@dptid": "113019942"}, "author": [{"preferred-name": {"ce:given-name": "S.", "ce:initials": "S.", "ce:surname": "Chittmittraprap", "ce:indexed-name": "Chittmittraprap S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Chittmittraprap", "@auid": "52263313100", "ce:indexed-name": "Chittmittraprap S."}, {"preferred-name": {"ce:given-name": "K.", "ce:initials": "K.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan K."}, "@seq": "3", "ce:initials": "K.", "@_fa": "true", "@type": "auth", "ce:surname": "Poovorawan", "@auid": "11141160200", "ce:indexed-name": "Poovorawan K."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Center of Excellence in Clinical Virology"}, {"$": "Department of Pediatrics"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "104425637"}, "@dptid": "104425637"}, "author": [{"preferred-name": {"ce:given-name": "U.", "ce:initials": "U.", "ce:surname": "Limothai", "ce:indexed-name": "Limothai U."}, "@seq": "4", "ce:initials": "U.", "@_fa": "true", "@type": "auth", "ce:surname": "Limothai", "@auid": "56784402300", "ce:indexed-name": "Limothai U."}, {"preferred-name": {"ce:given-name": "Y.", "ce:initials": "Y.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}, "@seq": "8", "ce:initials": "Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Poovorawan", "@auid": "7102786191", "ce:indexed-name": "Poovorawan Y."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pathology"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "100287552"}, "@dptid": "100287552"}, "author": [{"preferred-name": {"ce:given-name": "N.", "ce:initials": "N.", "ce:surname": "Wisedopas", "ce:indexed-name": "Wisedopas N."}, "@seq": "7", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Wisedopas", "@auid": "35577517700", "ce:indexed-name": "Wisedopas N."}]}], "citation-title": "A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response", "abstracts": "\u00a9 2015 John Wiley & Sons Ltd.Combining peginterferon (PEG-IFN) and a potent nucleoside/nucleotide analogue might improve treatment response in patients with chronic hepatitis B (CHB). The aims of this study were to compare the efficacy of PEG-IFN alpha-2b with or without entecavir in HBeAg-negative CHB and to investigate predictors of response. A total of 126 treatment-na\u00efve patients were randomly assigned to receive monotherapy (n = 63) or combination therapy (n = 63) for 48 weeks. Virological response (VR) was defined as HBV DNA level <2000 IU/mL at week 96. Baseline factors including polymorphisms in the IFNL3 (rs12979860) and HLA-DPA1 (rs3077) genes and on-treatment viral kinetics were determined. At week 48, rates of undetectable HBV DNA were lower in the monotherapy than combination groups, but rates of HBsAg clearance and decline were comparable. At week 96, there was no difference between the corresponding groups regarding virological response (41.3% vs 38.1%, P = 0.856), HBsAg clearance (9.5% vs 4.8%, P = 0.491) and HBsAg decline. Baseline HBsAg level [odds ratio (OR): 3.14 (1.34-7.69), P = 0.012] and rs3077 polymorphism [OR: 2.78 (1.27-6.11), P = 0.011] were independent predictors of response. Patients carried GG genotype of rs3077 with low baseline HBV (<1000 IU/mL) had high probability of achieving VR (76.5%) and HBsAg clearance (29.4%). None of the patients without decrease in HBsAg combined with <2 log10 HBV DNA decline at week 12 achieved a virological response. In conclusion, the combination therapy lead to greater on-treatment HBV DNA suppression but did not improve virological response and HBsAg clearance/decline over monotherapy. Host and viral factors could help optimize decision-making at baseline and during PEG-IFN-based therapy.", "correspondence": {"affiliation": {"country": "Thailand", "address-part": "Rama IV road", "postal-code": "10330", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Research Unit of Hepatitis and Liver Cancer"}, {"$": "Department of Biochemistry"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}]}, "person": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:degrees": "MD", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "entecavir", "@xml:lang": "eng"}, {"$": "HBsAg quantification", "@xml:lang": "eng"}, {"$": "peginterferon", "@xml:lang": "eng"}, {"$": "polymorphisms", "@xml:lang": "eng"}, {"$": "stopping rule", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "www.blackwell-science.com/jvh", "@type": "email"}}, "translated-sourcetitle": {"$": "Journal of Viral Hepatitis", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "23", "@issue": "6"}, "pagerange": {"@first": "427", "@last": "438"}}, "@type": "j", "sourcetitle": "Journal of Viral Hepatitis", "publicationdate": {"month": "06", "year": "2016", "date-text": {"@xfab-added": "true", "$": "1 June 2016"}, "day": "01"}, "codencode": "JVHEE", "sourcetitle-abbrev": "J. Viral Hepatitis", "@country": "gbr", "issn": [{"$": "13652893", "@type": "electronic"}, {"$": "13520504", "@type": "print"}], "publicationyear": {"@first": "2016"}, "publisher": {"publishername": "Blackwell Publishing Ltd", "ce:e-address": {"$": "customerservices@oxonblackwellpublishing.com", "@type": "email"}}, "@srcid": "25300"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}, {"classification-code": "4", "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"}, {"classification-code": "48", "classification-description": "Gastroenterology"}]}, {"@type": "ASJC", "classification": [{"$": "2721"}, {"$": "2725"}, {"$": "2406"}]}, {"@type": "SUBJABBR", "classification": [{"$": "MEDI"}, {"$": "IMMU"}]}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "142217-69-4"}, {"$": "209216-23-9"}], "chemical-name": "entecavir"}, {"cas-registry-number": "215647-85-1", "chemical-name": "peginterferon alpha2b"}, {"cas-registry-number": [{"$": "69257-39-2"}, {"$": "73-40-5"}], "chemical-name": "guanine"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Antiviral Agents"}, {"chemical-name": "DNA, Viral"}, {"chemical-name": "entecavir"}, {"chemical-name": "Guanine"}, {"chemical-name": "Hepatitis B e Antigens"}, {"chemical-name": "Hepatitis B Surface Antigens"}, {"chemical-name": "Interferon-alpha"}, {"chemical-name": "peginterferon alfa-2b"}, {"chemical-name": "Polyethylene Glycols"}, {"chemical-name": "Recombinant Proteins"}]}]}}, "grantlist": {"@complete": "y", "grant-text": {"$": "This work was funded by Merck, Sharp and Dohme Corp., and Grant for Chula Research Scholar, Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University. The study was also supported by Research Unit of Hepatitis and Liver Cancer and Center of Excellence in Clinical Virology, Chulalongkorn University.", "@xml:lang": "eng"}, "grant": [{"grant-acronym": "CU", "grant-agency": "Chulalongkorn University"}, {"grant-agency": "Merck"}]}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "EMBASE"}, {"$": "MEDL"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "06", "@year": "2017", "@timestamp": "BST 16:08:06", "@month": "11"}}, "itemidlist": {"itemid": [{"$": "606643615", "@idtype": "PUI"}, {"$": "641440730", "@idtype": "CAR-ID"}, {"$": "2015476824", "@idtype": "EMBASE"}, {"$": "26387494", "@idtype": "MEDL"}, {"$": "84945281416", "@idtype": "SCP"}, {"$": "84945281416", "@idtype": "SGR"}, {"$": "619058778", "@idtype": "PUIsecondary"}], "ce:doi": "10.1111/jvh.12467"}}, "tail": {"bibliography": {"@refcount": "47", "reference": [{"ref-fulltext": "Trepo C, Chan HL, Lok A,. Hepatitis B virus infection. Lancet 2014; 384: 2053-2063.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "84919848147", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "384"}, "pagerange": {"@first": "2053", "@last": "2063"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Trepo", "ce:indexed-name": "Trepo C."}, {"@seq": "2", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.L."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A."}]}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "54849146600", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "359"}, "pagerange": {"@first": "1486", "@last": "1500"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.L.", "@_fa": "true", "ce:surname": "Dienstag", "ce:indexed-name": "Dienstag J.L."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS,. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Management of hepatitis B: Summary of a clinical research workshop"}, "refd-itemidlist": {"itemid": {"$": "34247194561", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "1056", "@last": "1075"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.H.", "@_fa": "true", "ce:surname": "Hoofnagle", "ce:indexed-name": "Hoofnagle J.H."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Doo", "ce:indexed-name": "Doo E."}, {"@seq": "3", "ce:initials": "T.J.", "@_fa": "true", "ce:surname": "Liang", "ce:indexed-name": "Liang T.J."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Fleischer", "ce:indexed-name": "Fleischer R."}, {"@seq": "5", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A.S."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "84862664371", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57"}, "pagerange": {"@first": "167", "@last": "185"}}, "ref-text": "European Association for the Study of the Liver", "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Chronic hepatitis B: Update 2009"}, "refd-itemidlist": {"itemid": {"$": "70349240414", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "50"}, "pagerange": {"@first": "661", "@last": "662"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A.S."}, {"@seq": "2", "ce:initials": "B.J.", "@_fa": "true", "ce:surname": "McMahon", "ce:indexed-name": "McMahon B.J."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "4544239807", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "351"}, "pagerange": {"@first": "1206", "@last": "1217"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}, {"@seq": "2", "ce:initials": "G.K.", "@_fa": "true", "ce:surname": "Lau", "ce:indexed-name": "Lau G.K."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Bonino", "ce:indexed-name": "Bonino F."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Piccolo P, Lenci I, Demelia L, et al,. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14: 1165-1174.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "73449142131", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "1165", "@last": "1174"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Piccolo", "ce:indexed-name": "Piccolo P."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Lenci", "ce:indexed-name": "Lenci I."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Demelia", "ce:indexed-name": "Demelia L."}], "et-al": null}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy"}, "refd-itemidlist": {"itemid": {"$": "70349548852", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41"}, "pagerange": {"@first": "1100", "@last": "1104"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Suppiah", "ce:indexed-name": "Suppiah V."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Moldovan", "ce:indexed-name": "Moldovan M."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Ahlenstiel", "ce:indexed-name": "Ahlenstiel G."}], "et-al": null}, "ref-sourcetitle": "Nat Genet"}}, {"ref-fulltext": "Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C"}, "refd-itemidlist": {"itemid": {"$": "70349533037", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41"}, "pagerange": {"@first": "1105", "@last": "1109"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka Y."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Nishida", "ce:indexed-name": "Nishida N."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Sugiyama", "ce:indexed-name": "Sugiyama M."}], "et-al": null}, "ref-sourcetitle": "Nat Genet"}}, {"ref-fulltext": "Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance"}, "refd-itemidlist": {"itemid": {"$": "70349292099", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "461"}, "pagerange": {"@first": "399", "@last": "401"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Ge", "ce:indexed-name": "Ge D."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Fellay", "ce:indexed-name": "Fellay J."}, {"@seq": "3", "ce:initials": "A.J.", "@_fa": "true", "ce:surname": "Thompson", "ce:indexed-name": "Thompson A.J."}], "et-al": null}, "ref-sourcetitle": "Nature"}}, {"ref-fulltext": "Stattermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P,. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014; 39: 1059-1070.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Review article: Genetic factors that modify the outcome of viral hepatitis"}, "refd-itemidlist": {"itemid": {"$": "84899086264", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "39"}, "pagerange": {"@first": "1059", "@last": "1070"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.F.", "@_fa": "true", "ce:surname": "Stattermayer", "ce:indexed-name": "Stattermayer A.F."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Scherzer", "ce:indexed-name": "Scherzer T."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Beinhardt", "ce:indexed-name": "Beinhardt S."}, {"@seq": "4", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Rutter", "ce:indexed-name": "Rutter K."}, {"@seq": "5", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Hofer", "ce:indexed-name": "Hofer H."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ferenci", "ce:indexed-name": "Ferenci P."}]}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Kamatani Y, Wattanapokayakit S, Ochi H, et al,. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-595.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians"}, "refd-itemidlist": {"itemid": {"$": "67349160018", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "41"}, "pagerange": {"@first": "591", "@last": "595"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Kamatani", "ce:indexed-name": "Kamatani Y."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Wattanapokayakit", "ce:indexed-name": "Wattanapokayakit S."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Ochi", "ce:indexed-name": "Ochi H."}], "et-al": null}, "ref-sourcetitle": "Nat Genet"}}, {"ref-fulltext": "Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y,. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-123.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "69449102880", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46"}, "pagerange": {"@first": "117", "@last": "123"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Komolmit", "ce:indexed-name": "Komolmit P."}, {"@seq": "3", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Mahachai", "ce:indexed-name": "Mahachai V."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Sa-Nguanmoo", "ce:indexed-name": "Sa-Nguanmoo P."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Theamboonlers", "ce:indexed-name": "Theamboonlers A."}, {"@seq": "6", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}]}, "ref-sourcetitle": "J Clin Virol"}}, {"ref-fulltext": "Posuwan N, Payungporn S, Tangkijvanich P, et al,. Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population. PLoS ONE 2014; 9: e86007.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in Thai population"}, "refd-itemidlist": {"itemid": {"$": "84899798113", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "e86007"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Posuwan", "ce:indexed-name": "Posuwan N."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Payungporn", "ce:indexed-name": "Payungporn S."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}], "et-al": null}, "ref-sourcetitle": "PLoS ONE"}}, {"ref-fulltext": "Akkarathamrongsin S, Thong VD, Payungporn S, et al,. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol 2014; 86: 1482-1490.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6"}, "refd-itemidlist": {"itemid": {"$": "84903954168", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "86"}, "pagerange": {"@first": "1482", "@last": "1490"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Akkarathamrongsin", "ce:indexed-name": "Akkarathamrongsin S."}, {"@seq": "2", "ce:initials": "V.D.", "@_fa": "true", "ce:surname": "Thong", "ce:indexed-name": "Thong V.D."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Payungporn", "ce:indexed-name": "Payungporn S."}], "et-al": null}, "ref-sourcetitle": "J Med Virol"}}, {"ref-fulltext": "Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "1996"}, "ref-title": {"ref-titletext": "An algorithm for the grading of activity in chronic hepatitis C the METAVIR Cooperative Study Group"}, "refd-itemidlist": {"itemid": {"$": "0029778988", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "289", "@last": "293"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Bedossa", "ce:indexed-name": "Bedossa P."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Poynard", "ce:indexed-name": "Poynard T."}]}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients"}, "refd-itemidlist": {"itemid": {"$": "65449123444", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49"}, "pagerange": {"@first": "1151", "@last": "1157"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Moucari", "ce:indexed-name": "Moucari R."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Mackiewicz", "ce:indexed-name": "Mackiewicz V."}, {"@seq": "3", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Lada", "ce:indexed-name": "Lada O."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Rijckborst V, Hansen BE, Ferenci P, et al,. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a"}, "refd-itemidlist": {"itemid": {"$": "84859734382", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "1006", "@last": "1011"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Rijckborst", "ce:indexed-name": "Rijckborst V."}, {"@seq": "2", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Hansen", "ce:indexed-name": "Hansen B.E."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ferenci", "ce:indexed-name": "Ferenci P."}], "et-al": null}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Xie Q, Zhou H, Bai X, et al,. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \"e\" antigen-positive chronic hepatitis B. Clin Infect Dis 2014; 59: 1714-1723.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \"e\" antigen-positive chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84919621940", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "59"}, "pagerange": {"@first": "1714", "@last": "1723"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Xie", "ce:indexed-name": "Xie Q."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou H."}, {"@seq": "3", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Bai", "ce:indexed-name": "Bai X."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Lok AS, Trinh H, Carosi G, et al,. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143 (619-628): e611.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84865490229", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "143", "@issue": "619-628"}, "pagerange": {"@first": "e611"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Lok", "ce:indexed-name": "Lok A.S."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Trinh", "ce:indexed-name": "Trinh H."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Carosi", "ce:indexed-name": "Carosi G."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Reijnders JG, Rijckborst V, Sonneveld MJ, et al,. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir"}, "refd-itemidlist": {"itemid": {"$": "79951669706", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "54"}, "pagerange": {"@first": "449", "@last": "454"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.G.", "@_fa": "true", "ce:surname": "Reijnders", "ce:indexed-name": "Reijnders J.G."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Rijckborst", "ce:indexed-name": "Rijckborst V."}, {"@seq": "3", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}], "et-al": null}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Thompson AJ, Nguyen T, Iser D, et al,. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers"}, "refd-itemidlist": {"itemid": {"$": "77952716572", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51"}, "pagerange": {"@first": "1933", "@last": "1944"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.J.", "@_fa": "true", "ce:surname": "Thompson", "ce:indexed-name": "Thompson A.J."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Nguyen", "ce:indexed-name": "Nguyen T."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Iser", "ce:indexed-name": "Iser D."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Tseng TC, Liu CJ, Su TH, et al,. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-525, 525 e511-512.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters"}, "refd-itemidlist": {"itemid": {"$": "84984552614", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "141"}, "pagerange": {"@first": "517", "@last": "525"}}, "ref-text": "525 e511-512", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.C.", "@_fa": "true", "ce:surname": "Tseng", "ce:indexed-name": "Tseng T.C."}, {"@seq": "2", "ce:initials": "C.J.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu C.J."}, {"@seq": "3", "ce:initials": "T.H.", "@_fa": "true", "ce:surname": "Su", "ce:indexed-name": "Su T.H."}], "et-al": null}, "ref-sourcetitle": "Gastroenterology"}}, {"ref-fulltext": "Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P,. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int 2014; 34 (Suppl 1): 97-107.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "HBsAg quantification: Useful for monitoring natural history and treatment outcome"}, "refd-itemidlist": {"itemid": {"$": "84890865948", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "97", "@last": "107"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Martinot-Peignoux", "ce:indexed-name": "Martinot-Peignoux M."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lapalus", "ce:indexed-name": "Lapalus M."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Asselah", "ce:indexed-name": "Asselah T."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}]}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Chen YC, Jeng WJ, Chu CM, Liaw YF,. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012; 10: 297-302.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection"}, "refd-itemidlist": {"itemid": {"$": "84857194778", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "10"}, "pagerange": {"@first": "297", "@last": "302"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.C.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen Y.C."}, {"@seq": "2", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Jeng", "ce:indexed-name": "Jeng W.J."}, {"@seq": "3", "ce:initials": "C.M.", "@_fa": "true", "ce:surname": "Chu", "ce:indexed-name": "Chu C.M."}, {"@seq": "4", "ce:initials": "Y.F.", "@_fa": "true", "ce:surname": "Liaw", "ce:indexed-name": "Liaw Y.F."}]}, "ref-sourcetitle": "Clin Gastroenterol Hepatol"}}, {"ref-fulltext": "Seto WK, Wong DK, Fung J, et al,. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-819.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance"}, "refd-itemidlist": {"itemid": {"$": "84865535075", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "812", "@last": "819"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Seto", "ce:indexed-name": "Seto W.K."}, {"@seq": "2", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong D.K."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Fung", "ce:indexed-name": "Fung J."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "Chan HL, Wong GL, Tse CH, Chan HY, Wong VW,. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204: 408-414.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients"}, "refd-itemidlist": {"itemid": {"$": "79960113229", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "204"}, "pagerange": {"@first": "408", "@last": "414"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.L."}, {"@seq": "2", "ce:initials": "G.L.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong G.L."}, {"@seq": "3", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Tse", "ce:indexed-name": "Tse C.H."}, {"@seq": "4", "ce:initials": "H.Y.", "@_fa": "true", "ce:surname": "Chan", "ce:indexed-name": "Chan H.Y."}, {"@seq": "5", "ce:initials": "V.W.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong V.W."}]}, "ref-sourcetitle": "J Infect Dis"}}, {"ref-fulltext": "Kao JH,. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2014; 34 (Suppl. 1): 112-119.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "HBeAg-positive chronic hepatitis B: Why do i treat my patients with pegylated interferon?"}, "refd-itemidlist": {"itemid": {"$": "84890886957", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "112", "@last": "119"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.H.", "@_fa": "true", "ce:surname": "Kao", "ce:indexed-name": "Kao J.H."}]}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Bonino F, Marcellin P, Lau GK, et al,. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "34247538953", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "699", "@last": "705"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Bonino", "ce:indexed-name": "Bonino F."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}, {"@seq": "3", "ce:initials": "G.K.", "@_fa": "true", "ce:surname": "Lau", "ce:indexed-name": "Lau G.K."}], "et-al": null}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Rijckborst V, ter Borg MJ, Cakaloglu Y, et al,. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762-1769.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "77955383602", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "105"}, "pagerange": {"@first": "1762", "@last": "1769"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Rijckborst", "ce:indexed-name": "Rijckborst V."}, {"@seq": "2", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Ter Borg", "ce:indexed-name": "Ter Borg M.J."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Cakaloglu", "ce:indexed-name": "Cakaloglu Y."}], "et-al": null}, "ref-sourcetitle": "Am J Gastroenterol"}}, {"ref-fulltext": "Goulis I, Karatapanis S, Akriviadis E, et al,. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 2015; 35: 1540-1548.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients"}, "refd-itemidlist": {"itemid": {"$": "84927616416", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "35"}, "pagerange": {"@first": "1540", "@last": "1548"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Goulis", "ce:indexed-name": "Goulis I."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Karatapanis", "ce:indexed-name": "Karatapanis S."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Akriviadis", "ce:indexed-name": "Akriviadis E."}], "et-al": null}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Brunetto MR,. A new role for an old marker, HBsAg. J Hepatol 2010; 52: 475-477.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "A new role for an old marker, HBsAg"}, "refd-itemidlist": {"itemid": {"$": "77949659050", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "52"}, "pagerange": {"@first": "475", "@last": "477"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.R.", "@_fa": "true", "ce:surname": "Brunetto", "ce:indexed-name": "Brunetto M.R."}]}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Lampertico P, Vigano M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84874471701", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57"}, "pagerange": {"@first": "890", "@last": "896"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Lampertico", "ce:indexed-name": "Lampertico P."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Vigano", "ce:indexed-name": "Vigano M."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Cheroni", "ce:indexed-name": "Cheroni C."}], "et-al": null}, "ref-sourcetitle": "Hepatology"}}, {"ref-fulltext": "de Niet A, Takkenberg RB, Benayed R, et al,. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 475-481.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir"}, "refd-itemidlist": {"itemid": {"$": "84858664561", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47"}, "pagerange": {"@first": "475", "@last": "481"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "De Niet", "ce:indexed-name": "De Niet A."}, {"@seq": "2", "ce:initials": "R.B.", "@_fa": "true", "ce:surname": "Takkenberg", "ce:indexed-name": "Takkenberg R.B."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Benayed", "ce:indexed-name": "Benayed R."}], "et-al": null}, "ref-sourcetitle": "Scand J Gastroenterol"}}, {"ref-fulltext": "Holmes JA, Nguyen T, Ratnam D, et al,. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol 2013; 28: 861-866.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha"}, "refd-itemidlist": {"itemid": {"$": "84876999254", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28"}, "pagerange": {"@first": "861", "@last": "866"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Holmes", "ce:indexed-name": "Holmes J.A."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Nguyen", "ce:indexed-name": "Nguyen T."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Ratnam", "ce:indexed-name": "Ratnam D."}], "et-al": null}, "ref-sourcetitle": "J Gastroenterol Hepatol"}}, {"ref-fulltext": "Zhang Q, Lapalus M, Asselah T, et al,. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2014; 21: 525-532.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients"}, "refd-itemidlist": {"itemid": {"$": "84902257808", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "525", "@last": "532"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang Q."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lapalus", "ce:indexed-name": "Lapalus M."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Asselah", "ce:indexed-name": "Asselah T."}], "et-al": null}, "ref-sourcetitle": "J Viral Hepat"}}, {"ref-fulltext": "Brouwer WP, Sonneveld MJ, Tabak F, et al,. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2014; 40: 811-818.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84908090217", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "40"}, "pagerange": {"@first": "811", "@last": "818"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.P.", "@_fa": "true", "ce:surname": "Brouwer", "ce:indexed-name": "Brouwer W.P."}, {"@seq": "2", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Sonneveld", "ce:indexed-name": "Sonneveld M.J."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Tabak", "ce:indexed-name": "Tabak F."}], "et-al": null}, "ref-sourcetitle": "Aliment Pharmacol Ther"}}, {"ref-fulltext": "Cheng L, Sun X, Tan S, et al,. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res 2014; 44: 1000-1007.", "@id": "38", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients"}, "refd-itemidlist": {"itemid": {"$": "84907866020", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "44"}, "pagerange": {"@first": "1000", "@last": "1007"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Cheng", "ce:indexed-name": "Cheng L."}, {"@seq": "2", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Sun", "ce:indexed-name": "Sun X."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Tan", "ce:indexed-name": "Tan S."}], "et-al": null}, "ref-sourcetitle": "Hepatol Res"}}, {"ref-fulltext": "Seto WK, Wong DK, Kopaniszen M, et al,. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-1703.", "@id": "39", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "HLA-DP and IL28B polymorphisms: Influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84878294955", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "1695", "@last": "1703"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.K.", "@_fa": "true", "ce:surname": "Seto", "ce:indexed-name": "Seto W.K."}, {"@seq": "2", "ce:initials": "D.K.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong D.K."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Kopaniszen", "ce:indexed-name": "Kopaniszen M."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC,. Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. Genes Immun 2010; 11: 99-112.", "@id": "40", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Regulation of major histocompatibility complex class II gene expression, genetic variation and disease"}, "refd-itemidlist": {"itemid": {"$": "77649340368", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "11"}, "pagerange": {"@first": "99", "@last": "112"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Handunnetthi", "ce:indexed-name": "Handunnetthi L."}, {"@seq": "2", "ce:initials": "S.V.", "@_fa": "true", "ce:surname": "Ramagopalan", "ce:indexed-name": "Ramagopalan S.V."}, {"@seq": "3", "ce:initials": "G.C.", "@_fa": "true", "ce:surname": "Ebers", "ce:indexed-name": "Ebers G.C."}, {"@seq": "4", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Knight", "ce:indexed-name": "Knight J.C."}]}, "ref-sourcetitle": "Genes Immun"}}, {"ref-fulltext": "Vigano M, Invernizzi F, Lampertico P,. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? Liver Int 2015; 35 (Suppl 1): 107-113.", "@id": "41", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Optimal therapy of chronic hepatitis B: How do i treat my HBeAg-negative patients?"}, "refd-itemidlist": {"itemid": {"$": "84919665513", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "35"}, "pagerange": {"@first": "107", "@last": "113"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Vigano", "ce:indexed-name": "Vigano M."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Invernizzi", "ce:indexed-name": "Invernizzi F."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Lampertico", "ce:indexed-name": "Lampertico P."}]}, "ref-sourcetitle": "Liver Int"}}, {"ref-fulltext": "Brunetto MR, Marcellin P, Cherubini B, et al,. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59: 1153-1159.", "@id": "42", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype"}, "refd-itemidlist": {"itemid": {"$": "84887993086", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "59"}, "pagerange": {"@first": "1153", "@last": "1159"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.R.", "@_fa": "true", "ce:surname": "Brunetto", "ce:indexed-name": "Brunetto M.R."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Marcellin", "ce:indexed-name": "Marcellin P."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Cherubini", "ce:indexed-name": "Cherubini B."}], "et-al": null}, "ref-sourcetitle": "J Hepatol"}}, {"ref-fulltext": "Chen X, Chen W, Ma X, Huang J, Chen R,. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol 2014; 86: 1705-1713.", "@id": "43", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84926079007", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "86"}, "pagerange": {"@first": "1705", "@last": "1713"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen X."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen W."}, {"@seq": "3", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Ma", "ce:indexed-name": "Ma X."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Huang", "ce:indexed-name": "Huang J."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen R."}]}, "ref-sourcetitle": "J Med Virol"}}, {"ref-fulltext": "Lampertico P, Vigano M, Di Costanzo GG, et al,. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62: 290-298.", "@id": "44", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B"}, "refd-itemidlist": {"itemid": {"$": "84872079300", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62"}, "pagerange": {"@first": "290", "@last": "298"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Lampertico", "ce:indexed-name": "Lampertico P."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Vigano", "ce:indexed-name": "Vigano M."}, {"@seq": "3", "ce:initials": "G.G.", "@_fa": "true", "ce:surname": "Di Costanzo", "ce:indexed-name": "Di Costanzo G.G."}], "et-al": null}, "ref-sourcetitle": "Gut"}}, {"ref-fulltext": "Boglione L, D'Avolio A, Cariti G, et al,. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013; 20: e11-e19.", "@id": "45", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes"}, "refd-itemidlist": {"itemid": {"$": "84875217559", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20"}, "pagerange": {"@first": "e11", "@last": "e19"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Boglione", "ce:indexed-name": "Boglione L."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D'Avolio", "ce:indexed-name": "D'Avolio A."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Cariti", "ce:indexed-name": "Cariti G."}], "et-al": null}, "ref-sourcetitle": "J Viral Hepat"}}, {"ref-fulltext": "Moucari R, Boyer N, Ripault MP, et al,. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011; 18: 580-586.", "@id": "46", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients"}, "refd-itemidlist": {"itemid": {"$": "79960678798", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18"}, "pagerange": {"@first": "580", "@last": "586"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Moucari", "ce:indexed-name": "Moucari R."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Boyer", "ce:indexed-name": "Boyer N."}, {"@seq": "3", "ce:initials": "M.P.", "@_fa": "true", "ce:surname": "Ripault", "ce:indexed-name": "Ripault M.P."}], "et-al": null}, "ref-sourcetitle": "J Viral Hepat"}}, {"ref-fulltext": "Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P,. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol 2013; 58: 713-717.", "@id": "47", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs"}, "refd-itemidlist": {"itemid": {"$": "84888839700", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "713", "@last": "717"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Ouzan", "ce:indexed-name": "Ouzan D."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Penaranda", "ce:indexed-name": "Penaranda G."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Joly", "ce:indexed-name": "Joly H."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Khiri", "ce:indexed-name": "Khiri H."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Pironti", "ce:indexed-name": "Pironti A."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Halfon", "ce:indexed-name": "Halfon P."}]}, "ref-sourcetitle": "J Clin Virol"}}]}}}}, "affiliation": {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, "coredata": {"srctype": "j", "eid": "2-s2.0-84945281416", "dc:description": "Combining peginterferon (PEG-IFN) and a potent nucleoside/nucleotide analogue might improve treatment response in patients with chronic hepatitis B (CHB). The aims of this study were to compare the efficacy of PEG-IFN alpha-2b with or without entecavir in HBeAg-negative CHB and to investigate predictors of response. A total of 126 treatment-na\u00efve patients were randomly assigned to receive monotherapy (n = 63) or combination therapy (n = 63) for 48 weeks. Virological response (VR) was defined as HBV DNA level <2000 IU/mL at week 96. Baseline factors including polymorphisms in the IFNL3 (rs12979860) and HLA-DPA1 (rs3077) genes and on-treatment viral kinetics were determined. At week 48, rates of undetectable HBV DNA were lower in the monotherapy than combination groups, but rates of HBsAg clearance and decline were comparable. At week 96, there was no difference between the corresponding groups regarding virological response (41.3% vs 38.1%, P = 0.856), HBsAg clearance (9.5% vs 4.8%, P = 0.491) and HBsAg decline. Baseline HBsAg level [odds ratio (OR): 3.14 (1.34-7.69), P = 0.012] and rs3077 polymorphism [OR: 2.78 (1.27-6.11), P = 0.011] were independent predictors of response. Patients carried GG genotype of rs3077 with low baseline HBV (<1000 IU/mL) had high probability of achieving VR (76.5%) and HBsAg clearance (29.4%). None of the patients without decrease in HBsAg combined with <2 log10 HBV DNA decline at week 12 achieved a virological response. In conclusion, the combination therapy lead to greater on-treatment HBV DNA suppression but did not improve virological response and HBsAg clearance/decline over monotherapy. Host and viral factors could help optimize decision-making at baseline and during PEG-IFN-based therapy.", "pubmed-id": "26387494", "prism:coverDate": "2016-06-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84945281416", "dc:creator": {"author": [{"ce:given-name": "Pisit", "preferred-name": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, "@seq": "1", "ce:initials": "P.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "MD", "ce:surname": "Tangkijvanich", "@auid": "7003646635", "author-url": "https://api.elsevier.com/content/author/author_id/7003646635", "ce:indexed-name": "Tangkijvanich P."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84945281416"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84945281416&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84945281416&origin=inward"}], "source-id": "25300", "citedby-count": "31", "prism:volume": "23", "subtype": "ar", "dc:title": "A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response", "openaccess": "0", "prism:issn": "13652893 13520504", "publishercopyright": "\u00a9 2015 John Wiley & Sons Ltd.", "prism:issueIdentifier": "6", "subtypeDescription": "Article", "prism:publicationName": "Journal of Viral Hepatitis", "prism:pageRange": "427-438", "prism:endingPage": "438", "openaccessFlag": "false", "prism:doi": "10.1111/jvh.12467", "prism:startingPage": "427", "dc:identifier": "SCOPUS_ID:84945281416", "dc:publisher": "Blackwell Publishing Ltdcustomerservices@oxonblackwellpublishing.com"}, "idxterms": {"mainterm": [{"$": "Adolescent", "@weight": "b", "@candidate": "n"}, {"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Aged", "@weight": "b", "@candidate": "n"}, {"$": "Antiviral Agents", "@weight": "b", "@candidate": "n"}, {"$": "DNA, Viral", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Guanine", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B e Antigens", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B Surface Antigens", "@weight": "b", "@candidate": "n"}, {"$": "Hepatitis B, Chronic", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Interferon-alpha", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Polyethylene Glycols", "@weight": "b", "@candidate": "n"}, {"$": "Prospective Studies", "@weight": "b", "@candidate": "n"}, {"$": "Recombinant Proteins", "@weight": "b", "@candidate": "n"}, {"$": "Treatment Outcome", "@weight": "b", "@candidate": "n"}, {"$": "Viral Load", "@weight": "b", "@candidate": "n"}, {"$": "Young Adult", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "entecavir"}, {"@_fa": "true", "$": "HBsAg quantification"}, {"@_fa": "true", "$": "peginterferon"}, {"@_fa": "true", "$": "polymorphisms"}, {"@_fa": "true", "$": "stopping rule"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Hepatology", "@code": "2721", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Infectious Diseases", "@code": "2725", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Virology", "@code": "2406", "@abbrev": "IMMU"}]}, "authors": {"author": [{"ce:given-name": "Pisit", "preferred-name": {"ce:given-name": "Pisit", "ce:initials": "P.", "ce:surname": "Tangkijvanich", "ce:indexed-name": "Tangkijvanich P."}, "@seq": "1", "ce:initials": "P.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "MD", "ce:surname": "Tangkijvanich", "@auid": "7003646635", "author-url": "https://api.elsevier.com/content/author/author_id/7003646635", "ce:indexed-name": "Tangkijvanich P."}, {"preferred-name": {"ce:given-name": "S.", "ce:initials": "S.", "ce:surname": "Chittmittraprap", "ce:indexed-name": "Chittmittraprap S."}, "@seq": "2", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Chittmittraprap", "@auid": "52263313100", "author-url": "https://api.elsevier.com/content/author/author_id/52263313100", "ce:indexed-name": "Chittmittraprap S."}, {"preferred-name": {"ce:given-name": "K.", "ce:initials": "K.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan K."}, "@seq": "3", "ce:initials": "K.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Poovorawan", "@auid": "11141160200", "author-url": "https://api.elsevier.com/content/author/author_id/11141160200", "ce:indexed-name": "Poovorawan K."}, {"preferred-name": {"ce:given-name": "U.", "ce:initials": "U.", "ce:surname": "Limothai", "ce:indexed-name": "Limothai U."}, "@seq": "4", "ce:initials": "U.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Limothai", "@auid": "56784402300", "author-url": "https://api.elsevier.com/content/author/author_id/56784402300", "ce:indexed-name": "Limothai U."}, {"preferred-name": {"ce:given-name": "A.", "ce:initials": "A.", "ce:surname": "Khlaiphuengsin", "ce:indexed-name": "Khlaiphuengsin A."}, "@seq": "5", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Khlaiphuengsin", "@auid": "56784235600", "author-url": "https://api.elsevier.com/content/author/author_id/56784235600", "ce:indexed-name": "Khlaiphuengsin A."}, {"preferred-name": {"ce:given-name": "N.", "ce:initials": "N.", "ce:surname": "Chuaypen", "ce:indexed-name": "Chuaypen N."}, "@seq": "6", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Chuaypen", "@auid": "55885029700", "author-url": "https://api.elsevier.com/content/author/author_id/55885029700", "ce:indexed-name": "Chuaypen N."}, {"preferred-name": {"ce:given-name": "N.", "ce:initials": "N.", "ce:surname": "Wisedopas", "ce:indexed-name": "Wisedopas N."}, "@seq": "7", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Wisedopas", "@auid": "35577517700", "author-url": "https://api.elsevier.com/content/author/author_id/35577517700", "ce:indexed-name": "Wisedopas N."}, {"preferred-name": {"ce:given-name": "Y.", "ce:initials": "Y.", "ce:surname": "Poovorawan", "ce:indexed-name": "Poovorawan Y."}, "@seq": "8", "ce:initials": "Y.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Poovorawan", "@auid": "7102786191", "author-url": "https://api.elsevier.com/content/author/author_id/7102786191", "ce:indexed-name": "Poovorawan Y."}]}}}